Exact Mass: 337.01284100000004

Exact Mass Matches: 337.01284100000004

Found 24 metabolites which its exact mass value is equals to given mass value 337.01284100000004, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

tenoxicam

tenoxicam

C13H11N3O4S2 (337.0190966)


M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors

   

Tenoxicam

(3Z)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-2H,3H,4H-1λ⁶-thieno[2,3-e][1,2]thiazine-1,1,4-trione

C13H11N3O4S2 (337.0190966)


Tenoxicam is only found in individuals that have used or taken this drug. It is an antiinflammatory agent with analgesic and antipyretic properties, and is used to treat osteoarthritis and control acute pain.The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss. M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors

   

Sudoxicam

4-hydroxy-2-methyl-1,1-dioxo-N-(1,3-thiazol-2-yl)-2H-1lambda6,2-benzothiazine-3-carboxamide

C13H11N3O4S2 (337.0190966)


   

4-(2,5-Dihydroxypyrrol-1-yl)-N-(1,3-thiazol-2-yl)benzenesulfonamide

4-(2,5-Dihydroxy-1H-pyrrol-1-yl)-N-(1,3-thiazol-2-yl)benzene-1-sulphonamide

C13H11N3O4S2 (337.0190966)


   

4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid

4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid

C14H11NO5S2 (337.0078636)


   

HTS 01037

HTS 01037

C14H11NO5S2 (337.0078636)


HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.

   

(Ferrocenylmethyl)trimethylammonium Bromide

(Ferrocenylmethyl)trimethylammonium Bromide

C14H20BrFeN (337.01284100000004)


   

5-Bromo-N-(4-methoxybenzyl)-3-nitropyridin-2-amine

5-Bromo-N-(4-methoxybenzyl)-3-nitropyridin-2-amine

C13H12BrN3O3 (337.0061982)


   

ethyl 2-(broMoMethyl)-8-cyano-7-MethoxyiMidazo[1,2-a]pyridine-3-carboxylate

ethyl 2-(broMoMethyl)-8-cyano-7-MethoxyiMidazo[1,2-a]pyridine-3-carboxylate

C13H12BrN3O3 (337.0061982)


   

1-(4-(5-Bromopyridin-2-yl)piperazin-1-yl)-2,2,2-trifluoroethanone

1-(4-(5-Bromopyridin-2-yl)piperazin-1-yl)-2,2,2-trifluoroethanone

C11H11BrF3N3O (337.0037532)


   

4-[(4-CHLORO-2,5-DIMETHYLPHENYL)THIO]-3-NITROBENZOIC ACID

4-[(4-CHLORO-2,5-DIMETHYLPHENYL)THIO]-3-NITROBENZOIC ACID

C15H12ClNO4S (337.0175542)


   

N-[1-(4-Bromophenyl)ethyl]-5-fluoro salicylamide

N-[1-(4-Bromophenyl)ethyl]-5-fluoro salicylamide

C15H13BrFNO2 (337.011363)


   

Sudoxicam

Sudoxicam

C13H11N3O4S2 (337.0190966)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

   

5-[(6-Nitro-1,3-benzodioxol-5-yl)hydrazinylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione

5-[(6-Nitro-1,3-benzodioxol-5-yl)hydrazinylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione

C11H7N5O6S (337.01170420000005)


   
   
   
   
   

(L-cysteinato-kappaS~3~)(methyl)mercury

(L-cysteinato-kappaS~3~)(methyl)mercury

C4H9HgNO2S (337.00602940000005)


   

(E)-4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid

(E)-4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid

C14H11NO5S2 (337.0078636)


HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.

   

2-methyl-1,1,4-trioxo-N-(2-pyridinyl)-3H-thieno[2,3-e]thiazine-3-carboxamide

2-methyl-1,1,4-trioxo-N-(2-pyridinyl)-3H-thieno[2,3-e]thiazine-3-carboxamide

C13H11N3O4S2 (337.0190966)


   

2-[[5-(3-fluorophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(1,3,4-thiadiazol-2-yl)acetamide

2-[[5-(3-fluorophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(1,3,4-thiadiazol-2-yl)acetamide

C12H8FN5O2S2 (337.010344)


   
   

1-Hydroxy-1-oxo-3-methyl-3-butylbenziodoxazole

1-Hydroxy-1-oxo-3-methyl-3-butylbenziodoxazole

C11H16INO3 (337.0174896)